Director at Sensei Biotherapeutics (NASDAQ: SNSE) gains shares, options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Sensei Biotherapeutics director Stephen M. Hahn reported acquiring common shares through a preferred stock conversion and receiving a new stock option award. On June 15, 2026, 44,763 shares of Common Stock were acquired upon the conversion of 44.763 shares of Series B Preferred Stock, leaving him with 44,763 common shares directly owned.

Separately, on June 12, 2026, Hahn received a stock option for 25,000 shares of Common Stock at an exercise price of $13.00 per share. This option vests in 36 equal monthly installments and is expected to be fully vested by June 12, 2029, subject to his continued service with the company.

Insider Trade Summary

44.763 shares exercised/converted

Mixed 3 txns

Insider Hahn Stephen M.

Role null

Type	Security	Shares	Price	Value
Conversion	Series B Preferred Stock	44.763	$0.00	--
Conversion	Common Stock	44,763	$0.00	--
Grant/Award	Stock Option (right to buy)	25,000	$0.00	--

Holdings After Transaction: Series B Preferred Stock — 0 shares (Direct, null); Common Stock — 44,763 shares (Direct, null); Stock Option (right to buy) — 25,000 shares (Direct, null)

Footnotes (1)

Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date. Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger"). Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

Key Figures

Common shares acquired via conversion: 44,763 shares Series B Preferred converted: 44.763 shares Common shares held after conversion: 44,763 shares +3 more

6 metrics

Common shares acquired via conversion 44,763 shares Conversion of Series B Preferred Stock on June 15, 2026

Series B Preferred converted 44.763 shares Converted into Common Stock on June 15, 2026

Common shares held after conversion 44,763 shares Direct ownership following June 15, 2026 transaction

New stock option grant 25,000 shares Stock Option (right to buy) granted June 12, 2026

Option exercise price $13.00 per share Stock option on 25,000 shares of Common Stock

Option vesting period 36 months Monthly vesting to full vesting by June 12, 2029

Key Terms

Series B Preferred Stock, Stock Option (right to buy), Certificate of Designation of Preferences, Rights and Limitations, Agreement and Plan of Merger, +1 more

5 terms

Series B Preferred Stock financial

"each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock"

Series B preferred stock is a type of ownership share issued by a company that offers certain advantages over common stock, such as priority in receiving dividends or assets if the company is sold or liquidated. It is typically issued after an initial round of funding, making it a way for investors to support a company's growth while gaining some protections and benefits. This stock matters to investors because it often provides a more secure investment position with potential for future growth.

Stock Option (right to buy) financial

"The shares subject to the option vest and become exercisable in 36 equal monthly installments"

Certificate of Designation of Preferences, Rights and Limitations regulatory

"Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock"

Agreement and Plan of Merger regulatory

"Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer"

An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.

vesting financial

"The shares subject to the option vest and become exercisable in 36 equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/16/2026 - 04:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hahn Stephen M.

(Last)

(First)

(Middle)

C/O FAETH THERAPEUTICS, INC.

701 TILLERY STREET #12 #1010

(Street)

AUSTIN

TEXAS

78702

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ FTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/15/2026		C		44,763⁽¹⁾	A	⁽²⁾⁽³⁾	44,763	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$13	06/12/2026		A⁽⁴⁾		25,000		⁽⁴⁾	06/11/2036	Common Stock	25,000	$0	25,000	D
Series B Preferred Stock⁽¹⁾	⁽²⁾⁽³⁾	06/15/2026		C			44.763	⁽²⁾⁽³⁾	⁽²⁾⁽³⁾	Common Stock	44,763⁽¹⁾	⁽²⁾⁽³⁾	0	D

Explanation of Responses:

1. Subject to certain conditions set forth in the Certificate of Designation of Preferences, Rights and Limitations of the Series B Preferred Stock, each share of Series B Preferred Stock is convertible into 1,000 shares of the Issuer's Common Stock and has no expiration date.

2. Pursuant to February 17, 2026 Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Sapphire First Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Sapphire Second Merger Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Faeth Holdings Therapeutics, Inc. ("HoldCo") and Faeth Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of HoldCo ("Faeth"), First Merger Sub merged with and into HoldCo, with HoldCo surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, HoldCo merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, the "Merger").

3. Footnote continued: Upon the closing of the Merger, shares of outstanding common stock of HoldCo were converted into the right to receive shares of the Issuer's Series B Preferred Stock.

4. The shares subject to the option vest and become exercisable in 36 equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, or June 12, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

	/s/ Josiah Craver, Attorney-in-Fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Stephen M. Hahn report at SNSE?

Stephen M. Hahn reported acquiring 44,763 shares of Common Stock via conversion of Series B Preferred Stock and receiving a stock option for 25,000 shares at $13.00 per share, all held directly.

How many Sensei Biotherapeutics common shares did the preferred conversion create?

The conversion created 44,763 shares of Common Stock. This came from converting 44.763 shares of Series B Preferred Stock, each convertible into 1,000 common shares under the Series B Certificate of Designation.

What are the terms of Stephen M. Hahn’s new stock option at SNSE?

Hahn received a stock option for 25,000 shares of Common Stock at a $13.00 exercise price. The option vests in 36 equal monthly installments and becomes fully vested by June 12, 2029, if he remains in continuous service.

Does Stephen M. Hahn hold Sensei Biotherapeutics shares directly or indirectly?

All reported holdings are direct. After the June 15, 2026 conversion, he directly holds 44,763 shares of Common Stock, with no remaining Series B Preferred Stock reported in this filing.

How is the Series B Preferred Stock of Sensei Biotherapeutics structured?

Each share of Series B Preferred Stock is convertible into 1,000 shares of Common Stock and has no expiration date. Conversion is subject to conditions in the Certificate of Designation for the Series B Preferred Stock.

What merger transaction is referenced in Stephen M. Hahn’s Form 4 for SNSE?

The footnotes reference a February 17, 2026 Agreement and Plan of Merger involving Sensei Biotherapeutics, two merger subsidiaries, Faeth Holdings Therapeutics, Inc., and Faeth Therapeutics, LLC, after which HoldCo became a wholly owned subsidiary.